To our knowledge, this nomogram is the first model to predict long‐term 3‐ and 5‐year individual survival, combining tumor EGFR mutation status and treatment‐related factors in stage III NSCLC patients with CRT. The gene discussed is EGFR; the disease is neoplasm.